Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-09-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularheartleftcoronaryejection fraction
  Phrases that lowered it: breast cancerto investigatepatientsinvestigate thealanine
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 25 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 82 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports marked serious: 66.1% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 133906 (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 5.7% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 50 (lowers risk) · Sponsor's track record
• Maximum age: 75 (lowers risk) · Who can join
• Disease area, dermatology: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients NCT07668076 · started 2022 · scored riskier than 14% of active trials completed
• Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity NCT01724450 · started 2013 · scored riskier than 26% of active trials completed
• Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer NCT01051401 · started 2010 · scored riskier than 18% of active trials terminated
• Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification NCT02177175 · started 2014 · scored riskier than 56% of active trials completed
• Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab NCT01009918 · started 2010 · scored riskier than 91% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.